ECSP20080276A - Compuestos de purinona y su uso en el tratamiento del cáncer - Google Patents

Compuestos de purinona y su uso en el tratamiento del cáncer

Info

Publication number
ECSP20080276A
ECSP20080276A ECSENADI202080276A ECDI202080276A ECSP20080276A EC SP20080276 A ECSP20080276 A EC SP20080276A EC SENADI202080276 A ECSENADI202080276 A EC SENADI202080276A EC DI202080276 A ECDI202080276 A EC DI202080276A EC SP20080276 A ECSP20080276 A EC SP20080276A
Authority
EC
Ecuador
Prior art keywords
compounds
salts
cancer
treatment
methods
Prior art date
Application number
ECSENADI202080276A
Other languages
English (en)
Spanish (es)
Inventor
Martin Howard
Frederick Goldberg
Maurice Finlay
Attilla Ting
Original Assignee
Cancer Research Tech Ltd
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Tech Ltd, Astrazeneca Ab filed Critical Cancer Research Tech Ltd
Publication of ECSP20080276A publication Critical patent/ECSP20080276A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Measurement Of Radiation (AREA)
ECSENADI202080276A 2018-06-15 2020-12-11 Compuestos de purinona y su uso en el tratamiento del cáncer ECSP20080276A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862685325P 2018-06-15 2018-06-15

Publications (1)

Publication Number Publication Date
ECSP20080276A true ECSP20080276A (es) 2021-01-29

Family

ID=67107385

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202080276A ECSP20080276A (es) 2018-06-15 2020-12-11 Compuestos de purinona y su uso en el tratamiento del cáncer

Country Status (29)

Country Link
US (2) US11884671B2 (cg-RX-API-DMAC7.html)
EP (1) EP3807278B1 (cg-RX-API-DMAC7.html)
JP (1) JP7472044B2 (cg-RX-API-DMAC7.html)
KR (1) KR102793666B1 (cg-RX-API-DMAC7.html)
CN (1) CN112236431B (cg-RX-API-DMAC7.html)
AR (1) AR114971A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019287295B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020025127A2 (cg-RX-API-DMAC7.html)
CA (1) CA3102195A1 (cg-RX-API-DMAC7.html)
CL (1) CL2020003131A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020015758A2 (cg-RX-API-DMAC7.html)
CR (1) CR20200620A (cg-RX-API-DMAC7.html)
DO (1) DOP2020000241A (cg-RX-API-DMAC7.html)
EA (1) EA202190006A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP20080276A (cg-RX-API-DMAC7.html)
ES (1) ES2931448T3 (cg-RX-API-DMAC7.html)
IL (1) IL279370B2 (cg-RX-API-DMAC7.html)
JO (1) JOP20200315B1 (cg-RX-API-DMAC7.html)
MA (1) MA52886A (cg-RX-API-DMAC7.html)
MX (1) MX2020013570A (cg-RX-API-DMAC7.html)
NI (1) NI202000099A (cg-RX-API-DMAC7.html)
PE (1) PE20210003A1 (cg-RX-API-DMAC7.html)
PH (1) PH12020552148A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202012035WA (cg-RX-API-DMAC7.html)
TW (1) TWI820146B (cg-RX-API-DMAC7.html)
UA (1) UA126837C2 (cg-RX-API-DMAC7.html)
UY (2) UY38263A (cg-RX-API-DMAC7.html)
WO (1) WO2019238929A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202100195B (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI899080B (zh) 2019-05-27 2025-10-01 大陸商迪哲(江蘇)醫藥股份有限公司 Dna依賴性蛋白激酶抑制劑
WO2021104277A1 (zh) * 2019-11-25 2021-06-03 南京明德新药研发有限公司 作为dna-pk抑制剂的嘧啶并咪唑类化合物
KR102786205B1 (ko) * 2019-12-31 2025-03-31 청두 바이위 파머수티컬 씨오., 엘티디 퓨린 유도체 및 의학에서의 그의 용도
WO2021136461A1 (zh) * 2019-12-31 2021-07-08 成都百裕制药股份有限公司 嘌呤衍生物及其在医药上的应用
CN113121538B (zh) * 2019-12-31 2023-04-21 成都百裕制药股份有限公司 呋喃衍生物及其在医药上的应用
WO2021204111A1 (zh) * 2020-04-10 2021-10-14 南京明德新药研发有限公司 作为dna-pk抑制剂的氨基嘧啶化合物及其衍生物
BR112022020962A2 (pt) * 2020-04-17 2022-12-06 Chengdu Baiyu Pharmaceutical Co Ltd Derivados de imidazolidinona e uso médico dos mesmos
WO2021260583A1 (en) 2020-06-24 2021-12-30 Astrazeneca Uk Limited Combination of antibody-drug conjugate and dna-pk inhibitor
WO2022017368A1 (zh) * 2020-07-20 2022-01-27 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
CA3192868A1 (en) * 2020-09-24 2022-03-31 Auckland Uniservices Limited Novel aminopyridines and their use in treating cancer
CN114573605A (zh) * 2020-12-01 2022-06-03 武汉光谷亚太医药研究院有限公司 Dna依赖蛋白激酶抑制剂及其应用
TW202241901A (zh) * 2020-12-21 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮衍生物、其製備方法及其在醫藥上的應用
CN114656487B (zh) * 2020-12-22 2023-11-14 江苏恒瑞医药股份有限公司 稠合嘧啶类化合物、其制备方法及其在医药上的应用
CN114656486B (zh) * 2020-12-22 2023-09-19 江苏恒瑞医药股份有限公司 嘌呤酮类化合物、其制备方法及其在医药上的应用
TW202229281A (zh) * 2020-12-24 2022-08-01 大陸商江蘇恆瑞醫藥股份有限公司 嘌呤酮類化合物、其製備方法及其在醫藥上的應用
CN116917288B (zh) * 2021-03-22 2026-04-14 成都赜灵生物医药科技股份有限公司 一种7,9-二氢嘌呤衍生物及其制药用途
US20240300977A1 (en) * 2021-04-17 2024-09-12 Intellia Therapeutics, Inc. Inhibitors of dna-dependent protein kinase and compositions and uses thereof
CN117377676B (zh) * 2021-06-29 2026-04-07 康百达(四川)生物医药科技有限公司 嘌呤衍生物的晶型及其药物组合物
WO2023036156A1 (zh) * 2021-09-07 2023-03-16 首药控股(北京)股份有限公司 Dna-pk选择性抑制剂及其制备方法和用途
WO2025199376A1 (en) * 2024-03-22 2025-09-25 Padarn Therapeutics, Inc. Cdk2 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2212326A1 (en) * 2007-08-23 2010-08-04 AstraZeneca AB 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
WO2010118207A1 (en) * 2009-04-09 2010-10-14 Schering Corporation Pyrazolo [1, 5-a] pyrimidine derivatives as mtor inhibitors
JP5759471B2 (ja) * 2009-10-29 2015-08-05 ヴェクチュラ リミテッド Jak3キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
DE102010035744A1 (de) * 2010-08-28 2012-03-01 Merck Patent Gmbh Imidazolonylchinoline
MX2013010439A (es) * 2011-03-11 2014-07-09 Gilead Calistoga Llc Tratamientos combinados para neoplasias hematologicas.
EP2527344A1 (en) * 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
DK3558997T3 (da) * 2016-12-20 2021-04-19 Astrazeneca Ab Aminotriazolopyridinforbindelser og deres anvendelse til behandling af cancer

Also Published As

Publication number Publication date
CL2020003131A1 (es) 2021-04-30
KR102793666B1 (ko) 2025-04-08
EP3807278A1 (en) 2021-04-21
TWI820146B (zh) 2023-11-01
KR20210020944A (ko) 2021-02-24
US20210171525A1 (en) 2021-06-10
US20240150355A1 (en) 2024-05-09
SG11202012035WA (en) 2021-01-28
UY38263A (es) 2019-12-31
TW202035410A (zh) 2020-10-01
AU2019287295A1 (en) 2021-02-04
ZA202100195B (en) 2022-08-31
CA3102195A1 (en) 2019-12-19
PH12020552148A1 (en) 2021-07-05
IL279370B1 (en) 2024-07-01
MA52886A (fr) 2021-04-21
CN112236431A (zh) 2021-01-15
NI202000099A (es) 2021-09-24
AR114971A1 (es) 2020-11-11
CR20200620A (es) 2021-03-09
MX2020013570A (es) 2021-05-27
IL279370B2 (en) 2024-11-01
IL279370A (en) 2021-01-31
UA126837C2 (uk) 2023-02-08
JP7472044B2 (ja) 2024-04-22
CN112236431B (zh) 2024-02-13
JP2021527095A (ja) 2021-10-11
ES2931448T3 (es) 2022-12-29
EP3807278B1 (en) 2022-08-31
DOP2020000241A (es) 2021-04-30
EA202190006A1 (ru) 2021-03-29
WO2019238929A1 (en) 2019-12-19
US11884671B2 (en) 2024-01-30
NZ771886A (en) 2024-07-26
UY41072A (es) 2025-04-11
AU2019287295B2 (en) 2022-05-26
JOP20200315A1 (ar) 2020-12-07
BR112020025127A2 (pt) 2021-03-23
JOP20200315B1 (ar) 2024-04-18
CO2020015758A2 (es) 2021-04-30
PE20210003A1 (es) 2021-01-05

Similar Documents

Publication Publication Date Title
CO2020015758A2 (es) Compuestos de purinona y su uso en el tratamiento del cáncer
CO2019007810A2 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2018003969A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona
CO2018004933A2 (es) Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
UY33480A (es) Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
MX2019012847A (es) Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer.
MX2020012058A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cancer.
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
NI201900094A (es) COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER
CO2018010951A2 (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CO2020012484A2 (es) Inhibidores de secreción de proteínas basados en triazaciclododecansulfonamida ("tcd")